DCM
AKBA icon

Delpha Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Delpha Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,954
Closed -$29K – 168
2017
Q4 		$29K Buy
+1,954
New +$32.4K 0.03% 576

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Delpha Capital Management's AKBA Position: Q1 2018 in Review

Delpha Capital Management sold out of Akebia Therapeutics (AKBA) in Q1 2018, closing a stake of 1,954 shares — an estimated $29K sold.

Delpha Capital Management first reported a position in AKBA in Q4 2017 and held it in 1 quarter. The position peaked at $29K in Q4 2017. 153 funds tracked by Wall St. Rank hold AKBA as of Q1 2018.

  • Delpha Capital Management reported no remaining Akebia Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 1,954 Akebia Therapeutics shares in Q1 2018, an estimated $29K.
  • Delpha Capital Management first reported a position in Akebia Therapeutics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Akebia Therapeutics position peaked at $29K in Q4 2017.
  • 153 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.